Anders Waas
Directeur/Membre du Conseil chez ECTIN RESEARCH AB
Relations actives
| Nom | Sexe | Age | Sociétés liées | Collaboration |
|---|---|---|---|---|
| Christer Edlund | M | - | 11 ans | |
| Marie-Lois Ivarsson | M | - | 11 ans | |
| Peter Falk | M | - | 11 ans | |
| Anders Sandberg | M | 52 | 13 ans | |
| Petra Apell | M | 54 |
Texray AB
 Texray AB Packaged SoftwareTechnology Services Texray AB engages in development of medical technology products. It offers radiation protective textile. The company was founded by Petra Apell and Fredrik Gellerstedt and is headquartered in Göteborg, Sweden. | 12 ans |
| Fredrik Andersson | M | - | 4 ans | |
| Fredrik Gellerstedt | M | - |
Texray AB
Texray AB Packaged SoftwareTechnology Services Texray AB engages in development of medical technology products. It offers radiation protective textile. The company was founded by Petra Apell and Fredrik Gellerstedt and is headquartered in Göteborg, Sweden. | - |
| Carol Routledge | M | - | 6 ans | |
| Julian Aleksov | M | 59 | 1 ans | |
| Anders Torbjörn Ståhlberg | M | - |
Iscaff Pharma AB
 Iscaff Pharma AB Miscellaneous Commercial ServicesCommercial Services Iscaff Pharma AB develops platform and drugs for treatment of cancer. It develops a scaffold technology for drug development and treatment of cancer. The firm's products and services include development support; 3D printed scaffolds; licensing of technologies; and diagnostics. The company was founded by Göran Landberg and Anders Torbjörn Ståhlberg and is headquartered in Gothenburg, Sweden. | - |
| Karl Blom | M | 55 | 3 ans | |
| Per-Göran Gillberg | M | 68 | 4 ans | |
| Göran Landberg | M | - |
Iscaff Pharma AB
Iscaff Pharma AB Miscellaneous Commercial ServicesCommercial Services Iscaff Pharma AB develops platform and drugs for treatment of cancer. It develops a scaffold technology for drug development and treatment of cancer. The firm's products and services include development support; 3D printed scaffolds; licensing of technologies; and diagnostics. The company was founded by Göran Landberg and Anders Torbjörn Ståhlberg and is headquartered in Gothenburg, Sweden. | - |
| Kristina Torfgård | M | 61 | 5 ans | |
| Per Haag | M | - | - | |
| Lena Birgitta Degling Wikingsson | M | 61 | 4 ans | |
| Clas Malmeström | M | 59 | 9 ans | |
| Sebastian Hansson | M | - | 1 ans | |
| Austin Smith | M | - | 2 ans | |
| Kristofer Svensson | M | - | - | |
| Kirsten Harting | M | - | 1 ans | |
| Stefan Edgren | M | - | - | |
| Per Vult von Steyern | M | - | - | |
| Helena Ströberg | F | - | - | |
| Pernilla Linden | F | 55 |
Texray AB
Texray AB Packaged SoftwareTechnology Services Texray AB engages in development of medical technology products. It offers radiation protective textile. The company was founded by Petra Apell and Fredrik Gellerstedt and is headquartered in Göteborg, Sweden. | - |
| Stefan Pierrou | M | 59 | 3 ans | |
| Uri Peleg | M | - |
Texray AB
Texray AB Packaged SoftwareTechnology Services Texray AB engages in development of medical technology products. It offers radiation protective textile. The company was founded by Petra Apell and Fredrik Gellerstedt and is headquartered in Göteborg, Sweden. | - |
| Margareth Jorvid | F | 63 | 2 ans | |
| Ann-Charlotte Rosendahl | F | 61 |
Sobrera Pharma AB
 Sobrera Pharma AB Pharmaceuticals: MajorHealth Technology Sobrera Pharma AB is a Swedish pharmaceutical company that manufactures products for patients with alcohol use disorders. The company is based in Gothenburg, Sweden. The CEO of the company is Ann-Charlotte Rosendahl. | - |
| Jan Pilebjer | M | 70 |
Implexion Pharma AB
 Implexion Pharma AB Miscellaneous Commercial ServicesCommercial Services Implexion Pharma AB is a Swedish company that focuses on researching and developing drugs. The company is based in Gothenburg, Sweden. | 5 ans |
| Per Jesper Dahlberg | M | 60 |
Transmed Gothenburg AB
 Transmed Gothenburg AB Miscellaneous Commercial ServicesCommercial Services Transmed Gothenburg AB provides scientific and technical research and development services. The company is based in Gothenburg, Sweden. | - |
| Hans-Peter Albert Ostler | M | 53 | 2 ans | |
| Mats Johan Alm | M | 61 |
Texray AB
Texray AB Packaged SoftwareTechnology Services Texray AB engages in development of medical technology products. It offers radiation protective textile. The company was founded by Petra Apell and Fredrik Gellerstedt and is headquartered in Göteborg, Sweden. | 5 ans |
| Anna Sjöblom-Hallén | M | - | 8 ans | |
| Göran Gannedahl | M | 71 | 2 ans | |
| Kevan Cassidy | M | - | - |
Graphique Relationnel
Relation dans plusieurs entreprises
Anciennes relations
| Nom | Sexe | Age | Sociétés liées | Collaboration |
|---|---|---|---|---|
| Louis Lange | M | 72 |
CV Therapeutics, Inc.
 CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | 19 ans |
| Christopher Chai | M | 58 |
CV Therapeutics, Inc.
CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | 8 ans |
| Carlos de Sousa | M | 66 | - | |
| Pernilla Sandwall | F | 61 | - | |
| Kenneth Lee | M | 76 |
CV Therapeutics, Inc.
CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | 7 ans |
| Andrew Wolff | M | 69 |
CV Therapeutics, Inc.
CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | 10 ans |
| Huang I-Zu | M | - |
CV Therapeutics, Inc.
CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | 6 ans |
| David Banks | M | - |
CV Therapeutics, Inc.
CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | 4 ans |
| Hsiao Lieu | M | 53 |
CV Therapeutics, Inc.
CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | 3 ans |
| Cam Gallagher | M | 54 |
CV Therapeutics, Inc.
CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | 12 ans |
| Colin Hislop | M | 66 |
CV Therapeutics, Inc.
CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | 3 ans |
| Karl Fredrik Sjövall | M | 44 | - | |
| Markus Jerling | M | 72 |
CV Therapeutics, Inc.
CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | 4 ans |
| Rebecca Lucia | F | 52 |
CV Therapeutics, Inc.
CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | 1 ans |
| Shay Weisbrich | F | 71 |
CV Therapeutics, Inc.
CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | 1 ans |
| Michael T. Sweeney | M | 63 |
CV Therapeutics, Inc.
CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | 4 ans |
| Paul J. Frohna | M | - |
CV Therapeutics, Inc.
CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | 2 ans |
| Whedy Wang | M | 60 |
CV Therapeutics, Inc.
CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | 9 ans |
| Michael Owens | M | 68 | - | |
| Karin Walker | F | 60 |
CV Therapeutics, Inc.
CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | 3 ans |
| Per Wester | M | 64 | 4 ans | |
| Anders Bylock | M | 70 | 4 ans | |
| Johanna Hultgren | F | 37 | 2 ans | |
| Håkan Skogström | M | 63 | 4 ans | |
| Philip Wells | M | - |
CV Therapeutics, Inc.
CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | 1 ans |
| Jennifer Hodge | F | 55 |
CV Therapeutics, Inc.
CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | 7 ans |
| Bruce Philip Pritchard | M | 51 |
CV Therapeutics, Inc.
CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | 2 ans |
| Peter Hutt | M | 89 |
CV Therapeutics, Inc.
CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | 8 ans |
| Peter M. Strumph | M | 59 |
CV Therapeutics, Inc.
CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | 10 ans |
| Kenneth F. Boehm | M | - |
CV Therapeutics, Inc.
CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | 4 ans |
| R. Greer | M | 65 |
CV Therapeutics, Inc.
CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | 3 ans |
| Santo Costa | M | 78 |
CV Therapeutics, Inc.
CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | 8 ans |
| Costa G. Sevastopoulos | M | - |
CV Therapeutics, Inc.
CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | - |
| Barbara McNeil | M | 83 |
CV Therapeutics, Inc.
CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | 14 ans |
| Dan Spiegelman | M | 65 |
CV Therapeutics, Inc.
CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | 11 ans |
| David C. McCaleb | M | 70 |
CV Therapeutics, Inc.
CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | 10 ans |
| John Groom George | M | - |
CV Therapeutics, Inc.
CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | - |
| Louis Yu | M | 73 |
CV Therapeutics, Inc.
CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | 1 ans |
| Thomas Shenk | M | 77 |
CV Therapeutics, Inc.
CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | 5 ans |
| Brent Blackburn | M | 63 |
CV Therapeutics, Inc.
CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | 7 ans |
| Joseph M. Davie | M | 84 |
CV Therapeutics, Inc.
CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | 3 ans |
| Peter G. Milner | M | 68 |
CV Therapeutics, Inc.
CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | 17 ans |
| Huw Jones | M | 62 |
CV Therapeutics, Inc.
CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | - |
| Steven Glazer | M | 76 | - | |
| Thomas L. Gutshall | M | 85 |
CV Therapeutics, Inc.
CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | 15 ans |
| Anne Champsaur | M | - |
CV Therapeutics, Inc.
CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | 3 ans |
| Douglas T. Sheehy | M | 57 |
CV Therapeutics, Inc.
CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | 5 ans |
| Sandra Bevan | F | - | - |
Statistiques
| Pays | Relations | % du total |
|---|---|---|
| Suède | 42 | 50,00% |
| Etats-Unis | 38 | 45,24% |
Age des relations
Actives
Passées
Homme
Femme
Administrateurs
Exécutifs
Provenance des relations
- Bourse
- Insiders
- Anders Waas
- Réseau Personnel
